25+ Leading Medical Marijuana Pipeline Companies are working to improve the Treatment Landscape

DelveInsight's, "Medical Marijuana Canabidiol Pipeline Insight, 2023," report provides comprehensive insights about 25+ companies and 50+ pipeline drugs in Medical Marijuana Canabidiol pipeline landscape. It covers the Medical Marijuana pipeline drug profiles, including Medical Marijuana clinical trials and nonclinical stage products. It also covers the Medical Marijuana pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

For Medical Marijuana emerging drugs, the Medical Marijuana pipeline analysis report provides a 360° view of the Medical Marijuana pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Medical Marijuana pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

In the Medical Marijuana Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Medical Marijuana clinical trials studies, Medical Marijuana NDA approvals (if any), and product development activities comprising the technology, Medical Marijuana - Canabidiol collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Medical Marijuana Pipeline Report

• Over 25+ Medical Marijuana companies are evaluating 50+ Medical Marijuana pipeline therapies in various stages of development, and their anticipated acceptance in the Medical Marijuana market would significantly increase market revenue.

• The leading Medical Marijuana Companies includes Tetra Bio-Pharma, Corbus Pharmaceuticals, Bionorica SE, Jazz Pharmaceuticals, Medlab Clinical, Zynerba Pharmaceuticals, TO Pharmaceuticals, Therapix Biosciences, ANANDA Scientific, Botanix Pharmaceuticals, Arena Pharmaceuticals, Daisy Pharma Opioid Venture, Canbex Therapeutics, InMed Pharmaceuticals, Emerald Health Pharmaceuticals, MGC Pharmaceuticals, Echo Pharmaceuticals, Centrexion Therapeutics, Tilray, Artelo Biosciences, BOL Pharma, Receptor Life Sciences, AXIM Biotechnologies, Serina Therapeutics, EPM Group, GB Sciences, Cannovex, e3D Pharma, Phytecs, Zelira Therapeutics, Pascal Biosciences, Enveric Biosciences, MyMD Pharmaceuticals, Neuropathix, Can-Fite Pharma, Skye Bioscience, Vitality Biopharma, SciCann Therapeutics, Renew Biopharma, Aequus Pharmaceuticals, CURE Pharmaceuticals, Demeetra AgBio, and several others.

• Promising Medical Marijuana Pipeline Therapies includes Lenabasum, BX-1, Nabiximols, NanaBis, Zygel, THX-110, A1002N5S, BTX 1801, Olorinab, Dronabinol, VSN16R, INM-755, BTX 1503, EHP-101, CannEpil, CogniCann, Namisol, CNTX-6016, TN-TC11G, EV101, ART27.13, BOL-DP-o-08, BTX 1702, RLS102, RLS103, SER-228, EPM301, EPM305, EPM306, GBS.CP110, GBS.CP121, OCT-461201, CNX-001, CNX-002, CNX-003, CS-NEURO-1, CBIS-LC-001, CBIS-PC-001, CBIS-PPC-001, e3D-03, e3D-05, PECS-202, CBIS-OS-001, CBIS-SSA-001, MEM.PD119, PECS-101, PECS-112, PAS-403, PAS-393, KLS-13019, CNX-004, INM-088, EPM302, VBX-100, PLP-33, TopiCann, EPM303, EPM311, OWC-1808, and others.

• The Medical Marijuana Companies and academics are working to assess challenges and seek opportunities that could influence Medical Marijuana - Canabidiol R&D. The Medical Marijuana pipeline therapies under development are focused on novel approaches to treat/improve Medical Marijuana - Canabidiol.

Request a sample and discover the recent breakthroughs happening in Medical Marijuana pipeline landscape @ Medical Marijuana Pipeline Outlook Report- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Medical Marijuana Overview

The term medical marijuana refers to using the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness and other conditions. The U.S. Food and Drug Administration (FDA) has not recognized or approved the marijuana plant as medicine. However, the scientific study of the chemicals in marijuana, called canabinoids, has led to some FDA-approved medications that contain canabinoid chemicals in pill form. Continued research may lead to the approval of more medications. Since it contains chemicals it may help in treating a wide range of illnesses and symptoms; many people argue that it should be legal for medical purposes. A growing number of states have legalized marijuana for medical use. Medical marijuana is the medical use of sativa or indica plant to relieve symptoms of, or treat diseases and conditions. T

Recent Developmental Activities in the Medical Marijuana Treatment Landscape

• In June 2022, Zynerba Pharmaceuticals, Inc., presented an oral podium presentation and a poster presentation at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2022) that was held from May 31 - June 3, 2022. The presentation titled, "Long-Term Safety and Sustained Efficacy of ZYN002 Canabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017)," includes data demonstrating that in the ongoing long-term safety and efficacy trial of Zygel in children and adolescents with FXS, improvement was seen in Social Avoidance in the full population, with the greatest improvement in patients with complete methylation of their FMR1 gene.

• In May 2022, Corbus Pharmaceuticals announced that the National Institutes of Health sponsored Phase 2 study of lenabasum in systemic lupus erythematosus had completed its last patient visit and the clinical database had been locked. The Company is awaiting topline results. Corbus is pursuing potential partnerships to fund further development of lenabasum.

• In May 2022, Tetra Bio-Pharma Inc. announced that the European Medicines Agency (EMA) has classified PPP004 as an orphan medicinal product for the treatment for epidermolysis bullosa (EB). The designation represents PPP004's third orphan drug designation (ODD) as a treatment for EB.

• In January 2022, Emerald Health Pharmaceuticals Inc. received clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to begin enrolling patients in its Phase 2a clinical trial of EHP-101 for certain relapsing forms of multiple sclerosis (RMS), specifically relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).

• Pfizer Inc. and Arena Pharmaceuticals, Inc. announced on the 13th of December 2021, that the companies had entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per share in an all-cash transaction for the modest price of $6.7 billion. The boards of directors of both companies have unanimously approved the transaction. The deal is now expected to close in the first half of 2022, pending regulatory approvals.

• In May 2021, Jazz Pharmaceuticals announced the completion of its acquisition of GW Pharmaceuticals plc, a leader in the science, development and commercialization of canabinoid-based prescription medicines.

• In August 2021, MediPharm Labs Corp. announced that the Company's research partner McMaster University (the "Researcher") had received a no objection letter from Health Canada to proceed with research with MediPharm. This is a key milestone in moving forward with the Company's strategy to be the go-to partner for pharmaceuticals containing.

Find out more about the Medical Marijuana Diagnosis and Treatment of patients @ Medical Marijuana Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Medical Marijuana Emerging Drugs Profile

BX-1: Bionorica SE
BX-1 is an oral solution containing dronabinol, being developed by Bionorica. Dronabinol is a synthetic form of Δ⁹-TC, the primary psychoactive component of . The drug is currently in phase III stage of development for the treatment of spasticity in patients with multiple sclerosis not showing sufficient response to their current anti-spasticity treatment.

Lenabasum: Corbus Pharmaceuticals
Corbus Pharmaceuticals is developing Lenabasum, and currently it is in phase III stage of development for the treatment of multiple indications, such as dermatomyositis, systemic scleroderma, cystic fibrosis, systemic lupus erythematosus etc. Lenabasum is a novel, oral, small molecule that selectively binds as an agonist to the canabinoid receptor type 2 (CB2) and resolves inflammation and limits fibrosis in animal and human models of disease. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells.

THX-110: Therapix Biosciences
THX-110 is a being developed by Therapix Biosciences. The drug candidate platform is for the treatment of symptoms related to Tourette syndrome (TS), as well as obstructive sleep apnea (OSA) and chronic pain. Therapix is seeking orphan drug designation for this compound. The THX-110 program takes a unique approach to canabinoid formulation using the Entourage Effect hypothesis (i.e., in which endocanabinoid system constituents work synergistically together). THX-110 is a proprietary combination drug based on dronabinol and PEA. The drug is currently in phase II stage of development.

Canabis oil: TO Pharmaceuticals
TO Pharma is developing next-generation canabinoid therapies for debilitating diseases. TO pharmaceuticals is developing Canabis oil, and currently, it is in phase II stage of development for the treatment of hidradenitis suppurativa and agitation related to dementia. The canabis oil is made out of extract from the Avidekel strain and olive oil. Avidekel oil containing Δ9-Tetra-Hydrocannabinol (Δ9-TC) and Canabidiol in a 1:20 ratio and at a concentration of 30% and 1.5% Δ9-TC. Each Avidekel oil drop is approximately 0.04 mL in volume containing about 12 mg and 0.6 mg Δ9-TC. The oil is in the form of drops to be administered orally.

VSN16R: Canbex Therapeutics
VSN16R is currently in phase II stage of development for the treatment of spasticity in people with multiple sclerosis. The orally active small molecule compound is being developed by Canbex Therapeutics, a spin-off of University College London (UCL). Preclinical and Phase I clinical studies have demonstrated that VSN16R has the potential to provide substantially better patient care than existing systemic anti-spastic treatments. VSN16R was shown to be safe and well-tolerated in its Phase I clinical safety trial. In the Phase I study, 72 healthy volunteers were enrolled in a placebo-controlled, single ascending- and multiple-ascending dose design.

INM-755: InMed Pharmaceuticals
INM-755 is a cannabinol topical cream under development for the treatment of epidermolysis bullosa. INM-755 cream for EB is the first, and currently the only, cannabinol formulation being tested in clinical trials as a therapeutic product. The Phase 2 study, 755-201-EB, is designed to enroll up to 20 patients, conservatively within 10-12 months, and will take place at 10 pre-qualified clinical sites in several countries. All four subtypes of inherited EB, being EB Simplex, Dystrophic EB, Junctional EB, and Kindler Syndrome, are eligible for this study in which InMed will evaluate the safety of INM-755 (cannabinol) cream and its preliminary efficacy in treating symptoms and healing wounds over a 28-day period.

Medical Marijuana Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Medical Marijuana - Canabidiol. The Medical Marijuana companies which have their Medical Marijuana - Canabidiol drug candidates in the most advanced stage, i.e. Phase III include, Bionorica SE.

Understand more about the Medical Marijuana Pipeline Therapeutics Assessment, visit here for Medical Marijuana Pipeline Drugs Assessment @ https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Medical Marijuana Pipeline Segmentation

Phases
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Molecule Types
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Discover more about the list of Medical Marijuana FDA-approved drugs for Medical Marijuana @ Medical Marijuana Treatment Landscape- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Medical Marijuana Pipeline Report

• Coverage- Global

• Medical Marijuana Companies- Tetra Bio-Pharma, Corbus Pharmaceuticals, Bionorica SE, Jazz Pharmaceuticals, Medlab Clinical, Zynerba Pharmaceuticals, TO Pharmaceuticals, Therapix Biosciences, ANANDA Scientific, Botanix Pharmaceuticals, Arena Pharmaceuticals, Daisy Pharma Opioid Venture, Canbex Therapeutics, InMed Pharmaceuticals, Emerald Health Pharmaceuticals, MGC Pharmaceuticals, Echo Pharmaceuticals, Centrexion Therapeutics, Tilray, Artelo Biosciences, BOL Pharma, One World Canabis, Receptor Life Sciences, AXIM Biotechnologies, Serina Therapeutics, EPM Group, GB Sciences, Cannovex, e3D Pharma, Phytecs, Zelira Therapeutics, Pascal Biosciences, Enveric Biosciences, MyMD Pharmaceuticals, Neuropathix, Can-Fite Pharma, Skye Bioscience, Vitality Biopharma, SciCann Therapeutics, Renew Biopharma, Aequus Pharmaceuticals, CURE Pharmaceuticals, Demeetra AgBio, and others.

• Medical Marijuana Pipeline Therapies- Lenabasum, BX-1, Nabiximols, NanaBis, Zygel, THX-110, A1002N5S, BTX 1801, Olorinab, Dronabinol, VSN16R, INM-755, BTX 1503, EHP-101, CannEpil, CogniCann, Namisol, CNTX-6016, TN-TC11G, EV101, ART27.13, BOL-DP-o-08, BTX 1702, RLS102, RLS103, SER-228, EPM301, EPM305, EPM306, GBS.CP110, GBS.CP121, OCT-461201, CNX-001, CNX-002, CNX-003, CS-NEURO-1, CBIS-LC-001, CBIS-PC-001, CBIS-PPC-001, e3D-03, e3D-05, PECS-202, CBIS-OS-001, CBIS-SSA-001, MEM.PD119, PECS-101, PECS-112, PAS-403, PAS-393, KLS-13019, CNX-004, INM-088, EPM302, VBX-100, PLP-33, TopiCann, EPM303, EPM311, OWC-1808, and others

• Medical Marijuana Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for Medical Marijuana Emerging Therapies and Medical Marijuana Ongoing Clinical Trials; visit @ Medical Marijuana Companies- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Medical Marijuana - Canabidiol: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. BX-1: Bionorica SE
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. THX-110: Therapix Biosciences
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I/II)
13. CNTX 6016: Centrexion Therapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Medical Marijuana - Canabidiol Key Companies
17. Medical Marijuana - Canabidiol Key Products
18. Medical Marijuana - Canabidiol- Unmet Needs
19. Medical Marijuana - Canabidiol- Market Drivers and Barriers
20. Medical Marijuana - Canabidiol- Future Perspectives and Conclusion
21. Medical Marijuana - Canabidiol Analyst Views
22. Medical Marijuana - Canabidiol Key Companies
23. Appendix

For further information on the Medical Marijuana Pipeline therapeutics, reach out @ Medical Marijuana Market Drivers and Barriers- https://www.delveinsight.com/sample-request/medical-marijuana-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.